GYRE Insider Trading
Insider Ownership Percentage: 19.52%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $509,921.30
Gyre Therapeutics Share Price & Price History
Current Price: $10.80
Price Change: ▼ Price Decrease of -0.13 (-1.19%)
As of 01/16/2025 05:00 PM ET
Gyre Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/15/2025 | Songjiang Ma | President | Sell | 2,000 | $10.85 | $21,700.00 | 2,911,138 |  |
| 1/13/2025 | Songjiang Ma | President | Sell | 56 | $10.10 | $565.60 | 2,915,138 | |
| 1/10/2025 | Songjiang Ma | President | Sell | 1,057 | $10.02 | $10,591.14 | 2,915,194 | |
| 1/6/2025 | Songjiang Ma | President | Sell | 941 | $10.16 | $9,560.56 | 2,917,526 | |
| 1/2/2025 | Songjiang Ma | President | Sell | 2,000 | $12.40 | $24,800.00 | 2,920,467 | |
| 12/30/2024 | Songjiang Ma | President | Sell | 2,000 | $12.50 | $25,000.00 | 2,924,467 | |
| 12/26/2024 | Songjiang Ma | President | Sell | 2,000 | $12.70 | $25,400.00 | 2,928,467 | |
| 12/23/2024 | Songjiang Ma | President | Sell | 2,000 | $12.27 | $24,540.00 | 2,932,467 | |
| 12/19/2024 | Songjiang Ma | President | Sell | 2,000 | $10.82 | $21,640.00 | 2,936,467 | |
| 12/17/2024 | Songjiang Ma | President | Sell | 2,000 | $11.05 | $22,100.00 | 2,940,467 | |
| 6/28/2024 | Nassim Usman | Director | Sell | 3,452 | $12.00 | $41,424.00 | 1,636 | |
| 5/1/2024 | Nassim Usman | Director | Sell | 20,000 | $14.13 | $282,600.00 | 1,636 | |
| 1/3/2024 | Songjiang Ma | President | Sell | 833 | $11.85 | $9,871.05 | 2,918,467 | |
Gyre Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 11/19/2024 | Barclays PLC | 9,288 | $0.12M | 0.0% | +281.8% | 0.010% |  |
| 11/16/2024 | Geode Capital Management LLC | 303,647 | $3.81M | 0.0% | +16.9% | 0.325% | |
| 11/15/2024 | Barclays PLC | 9,288 | $0.12M | 0.0% | +281.8% | 0.010% | |
| 11/15/2024 | State Street Corp | 104,490 | $1.31M | 0.0% | +8.8% | 0.112% | |
| 11/13/2024 | FMR LLC | 3,742 | $47K | 0.0% | N/A | 0.004% | |
| 11/13/2024 | Advantage Alpha Capital Partners LP | 26,634 | $0.33M | 0.1% | N/A | 0.029% | |
| 11/12/2024 | Charles Schwab Investment Management Inc. | 113,648 | $1.43M | 0.0% | +392.2% | 0.122% | |
| 8/14/2024 | Marshall Wace LLP | 10,720 | $0.13M | 0.0% | -58.0% | 0.013% | |
| 8/9/2024 | Renaissance Technologies LLC | 13,900 | $0.17M | 0.0% | N/A | 0.016% | |
| 8/9/2024 | WINTON GROUP Ltd | 18,467 | $0.22M | 0.0% | N/A | 0.022% | |
| 8/1/2024 | Rhumbline Advisers | 10,291 | $0.12M | 0.0% | N/A | 0.012% | |
| 7/26/2024 | Bank of New York Mellon Corp | 18,266 | $0.22M | 0.0% | N/A | 0.021% | |
| 5/10/2024 | Vanguard Group Inc. | 195,098 | $3.41M | 0.0% | -1.5% | 0.228% | |
Data available starting January 2016
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
Read More on Gyre Therapeutics
Today's Range
Now: $10.80
52 Week Range
Now: $10.80
Volume
78,155 shs
Average Volume
142,305 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.98
Who are the company insiders with the largest holdings of Gyre Therapeutics?
